	S0337PAT Data Dictionary									
Column										
Number	Variable	Var. Label		Units	Code	Code Definition	Notes			
1	ALTPATID	Patient ID	Char			o				
2	TRNO	Treatment (N)	Num		2	Gemcitabine Saline Only				
-			Num		Gemcitabine					
3	TXLABEL	Treatment	Char		Saline Only					
		Troutient			1	Occurrence: First occurrence				
4	LEV1	Stratification Factor 1 (N)	Num		2	Occurrence: Recurrent disease				
					Occurrence: First occurrence					
5	LEVID1	Stratification Factor 1	Char		Occurrence: Recurrent disease					
					1	Sites: One tumor				
6	LEV2	Stratification Factor 2 (N)	Num		2	Sites: Two or more tumors				
7	LEVID2	Stratification Factor 2	Char		Sites: One tumor Sites: Two or more tumors					
		Age	_	Years	Siles. Two of more furnors					
0	AGE		Onai		F	Female				
9	SEX	Sex	Char		M	Male				
					N					
10	NATIVE	Native American	Char		Y					
					Ν					
11	ASIAN	Asian	Char		Y					
					N					
		Black/African American	Char		Y					
13	PACIFIC	Pacific Islander	Char		N N					
14	WHITE	White	Char		Y					
14	WINIE	Winte	Griai		N					
15	UNKRACE	Unknown Race	Char		Y					
					0					
					1					
					2					
16	SWOGPF	Zubrod PS	Char		3					
					CUR	Current				
47					FOR	Former				
17	SMOKEHX	Smoking History	Char		NEV	Never				
		Drive Internetical Transformet for Dividing			N					
18		Prior Intravesical Treatment for Bladder Cancer?	Char		Y					
10			ona		Adriamycin					
					BCG	Bacillus Calmette-Guerin				
					MMC	Mitomycin-C				
19	IMMUNOSP	Type of Intravesicle Treatment	Char		Not specified					
					N					
		Eligible Population	Char		Y					
21	ELIGNOTE	Ineligible Reasons	Char							
22	TURBT	TURBT Performed?	Char		N Y					
		Reason TURBT Not Performed	Char		1					
20	TORDITOTE		ona		N					
24	INSTILL	Assigned Instillation Given to Patient?	Char		Y					
					medical problem					
25	INSTNOTE	Reason TURBT But No Instillation	Char		refused or logistical					
					N					
		Per Protocol Population	Char		Y					
27	PERPROTNOTE	Per Protocol Notes	Char							
					T1					
28	PP_STG	Stage at TURBT, Only if PP	Char		TaN					
29	TOXPOP	Adverse Event Population	Char		Y		Due to data cleaning efforts, data may contain slight discrepancies from that reported in Figure 2 in the publication.			
		·			N					
			1		UNK					
30	BCGPLAN	Plan to Get BCG: Y/N/UNK	Char		Y					
					N					
			-							

31	RETURBT	Repeat TURBT within 6 weeks?	Char	1	Y				
51	INE FOREF	Repeat FORDT within 0 weeks:	Onai		0	Censored at Last Contact			
32	SURIND	Overall Survival Indicator	Num		1	Death Indicator			
52	OUTIND		Num		-	Death indicator	If Death: Date of Death - Date of Trial Registration		
33	SURTIM	Overall Survival Time	Num	Days			If No Death: Date of Last Contact - Date of Trial Registration		
00			Turin	Days	0	Censored at Last Contact			
34	MIBC	Muscle Invasive BC Indicator	Num		1	Progessed to MIBC			
54	IVIIDC		INUITI		1	Flogessed to MIDC	If MIBC: Date MIBC Progression identified - Date of Trial Registration		
35	TTMIBC	Time to MIBC	Num	Days			If No MIBC: Date of Last Contact - Date of Trial Registration		
				Days	Hi	High Grade MIBC			
					Low	Low Grade MIBC			
36	CYSTECT	MIBC Progression Grade Cystectomy Indicator	Char		None	No Cancer Found			
50					0	No Cystectomy Performed			
27					1	Cystectomy Performed			
31			Num		0	Censored at Last Contact			
20	C RISK	Competing Risk Indicator Cystectomy or Non-BC Death	Num		1	Competing Risk Event			
30	C_RISK		INUITI		0	Competing Risk Event			
			N		0				
39	RELIND	Recurrence Indicator	Num		1	Recurrence Indicator	If Recurrence: Date of Recurrence - Date of Trial Registration		
40	RELTIME	Recurrence Free Survival Time	Niuma	Days			If No Recurrence: Date of Last Contact - Date of Trial Registration		
40	RELINIE	Recurrence Free Survival Time	num	Days	0	Censored at Last Contact	in to recurrence. Date of Last Contact - Date of That Registration		
		Recurrence + Competing Risk Indicator			0	Recurrence Indicator			
41	RELIND2		Num		1				
					2	Competing Risk Event			
							If Censored: Date of Last Contact - Date of Trial Registration		
		Recurrence + Competing Risk Free					If Recurrence Event: Date of First Observation of Recurrent Disease - Date of Study Registration		
42	RELTIME2	Survival Time	Num	Days			If Competing Risk: Min(Date of Cystectomy - Date of Study Registration, Date of non-BC Death - Date of Study Registration)		
				20,0	N				
43	HIGRRECUR	High Grade Recurrence?	Char		Y				
40			onar		N				
11	CYSTO6MO	Cystectomy at 6 Months?	Char		Y				
			Onai		N				
45		Cystectomy Prior to Recurrence?	Char		Y				
40	CISIFRERECOR	Cystectomy Filor to Recurrence?	Gilai		Complete				
					Died				
10			0						
46	FOLLOW4YR	4 Year Follow-Up Status	Char		Lost				
					Low-grade disease (prespecified				
					target population)				
					No Trt, Medical				
					No Trt, Refuse				
					Not Eligible				
					Tx, High Grade				
					Tx, No Cancer/Inadequate				
					Pathology				
47	CENSORREASON	Follow-Up Censor Note	Char		Tx, T2 Stage				
	NOTE: Missing Data represented by blanks (' ')								

.

NOTE: Missing Data represented by blanks (' ')